Mission and Focus:
PolyImmunex LLC is a biopharmaceutical company developing potent new adjuvant and vaccine formulations for enhanced treatment and protection against a wide variety of infectious diseases and cancers. These include proprietary multi-functional nanoparticle delivery systems that incorporate antigens, adjuvants and targeting ligands that are capable of generating optimized and tailored immune responses. PolyImmunex LLC is also developing a universal cationic immunostimulatory nanoparticle adjuvant (CINATM) capable of enhancing a wide variety of biological and chemical adjuvants and improving immune responses to a broad range of antigens. The CINA platform has been engineered to mimic the shape and morphology of pathogens that host immune systems have naturally evolved to quickly respond to. As such, our adjuvants and delivery systems are capable of generating robust rapid humoral and cellular antigen-specific immune responses. The CINA platform can be applied to vaccines used to treat a wide variety of infectious diseases and in particular cancers. PolyImmunex LLC is founded on technologies that have been developed and patented by Prof. Salem, an expert in the development of novel drug, gene and vaccine delivery systems and collaborators that are experts in immunology, vaccines and cancer research.